Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV
types (PATRICIA): Final analysis of a double-blind, randomised study in young women.
Cross-protective efficacy of HPV-16/18 AS04adjuvanted vaccine against cervical infection and pre-cancer caused by non-vaccine oncogenic HPV
types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
In 2014 Gardasil 9 was approved to extend coverage to an additional 5 oncogenic HPV
types (31, 33, 45, 52, and 58), now covering an additional 20% of cervical cancers, and in 2015 Gardasil 9 indications were expanded to include boys and men 9 to 26 years of age.
2, 2018 (HealthDay News) -- Continuing regular cytology screening up to age 75 years or performing an exit human papillomavirus (HPV) test to confirm the absence of oncogenic HPV
strains past the age of 55 years offers preventive benefit for older women with a cervix, according to a study published online Nov.
They observed elevated levels of the two biomarkers, which have been associated with a faster clearance of oncogenic HPV
Efficacy of human papillomavirus (HPV) - 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV
types ( PATRICIA ): final analysis of a doubleblind, randomised study in young women.
In addition, oestrogen acts as an anti-apoptotic agent permitting proliferation of cells infected with oncogenic HPV
. It has been reported that steroid hormones found in oral contraceptives may affect the HPV genome and increase viral expression of oncoproteins E6 and E7.
In the past two decades, Human Papilloma Virus (HPV) strains have been identified as a causative agent in cervical cancer in particular with high grade oncogenic HPV
genotypes, such as HPV-16 and HPV-18, along with some other factors predispose women to cancer10,11.
The PCR method used in this study shows that oncogenic HPV
DNA E6 and E7 from HPV-18 are in a significant proportion of the NPC cases studied.
The 9-valent vaccine would prevent a broader range of oncogenic HPV
Local data from Africa on the relationship between oncogenic HPV
types, immune status and cervical preinvasive lesions are also incomplete.
Urban and rural populations live in different socioeconomic environments, lifestyles and life standards, which might explain the higher prevalence of overall HPV, oncogenic HPV
and multiple-genotype HPV infections in urban populations.